ID: ALA449775

Max Phase: Preclinical

Molecular Formula: C9H17F3O4S

Molecular Weight: 278.29

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCS(=O)(=O)CC(O)(O)C(F)(F)F

Standard InChI:  InChI=1S/C9H17F3O4S/c1-2-3-4-5-6-17(15,16)7-8(13,14)9(10,11)12/h13-14H,2-7H2,1H3

Standard InChI Key:  DGUDHQGBROOISV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 278.29

Molecular Weight (Monoisotopic): 278.0800

AlogP: 1.22

#Rotatable Bonds: 7

Polar Surface Area: 74.60

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.64

CX Basic pKa:

CX LogP: 1.35

CX LogD: 1.15

Aromatic Rings: 0

Heavy Atoms: 17

QED Weighted: 0.54

Np Likeness Score: -0.35

References

1. Harada T, Nakagawa Y, Wadkins RM, Potter PM, Wheelock CE..  (2009)  Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis.,  17  (1): [PMID:19062296] [10.1016/j.bmc.2008.11.008]

2. Wheelock CE, Severson TF, Hammock BD..  (2001)  Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility.,  14  (12): [PMID:11743738] [10.1021/tx015508+]

3. Mouchlis VD, Morisseau C, Hammock BD, Li S, McCammon JA, Dennis EA..  (2016)  Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A₂.,  24  (20): [PMID:27320659] [10.1016/j.bmc.2016.05.009]

Source

Source(1):

• Scientific Literature